Growth trajectory LabCorp Clinical Trials is expanding its footprint through acquisitions and facility expansions, including the Pathology Associates of Alabama acquisition and a new remodeled Dodge City facility, signaling opportunities to offer end-to-end clinical testing and integrated diagnostic solutions for a broader network.

Genetic health The Marker by Labcorp Genetic Health Panel launch creates a direct-to-consumer entry point for genetic screening, presenting a cross-sell opportunity to healthcare providers and employers seeking to integrate scalable genetic risk assessments into patient care and preventive programs.

Strategic spin-off The July 2026 spin-off of Fortrea indicates a refocused emphasis within LabCorp on diagnostics and clinical trial services, suggesting sales angles around integrated lab diagnostics combined with drug development support for biopharma clients.

Digital and automation LabCorp’s technology stack including SAP maintenance, Oracle Eloqua, and open AI tools points to a readiness for streamlined data integration, marketing automation, and AI-enabled trial operations—opportunities to propose enhanced data management, patient recruitment, and analytics services.

Network scale With a growing network of over 2,200 testing facilities and a broad client base across physicians, payers, hospitals, and biopharma, there is potential to upsell comprehensive end-to-end solutions and cross-sell service lines to existing and new clients seeking integrated health diagnostics and clinical development capabilities.